Array Technologies (ARRY)
(Real Time Quote from BATS)
$12.48 USD
-0.05 (-0.40%)
Updated Apr 30, 2024 12:30 PM ET
2-Buy of 5 2
A Value A Growth D Momentum A VGM
Brokerage Reports
0 items in cart
[ARRY]
Reports for Purchase
Showing records 501 - 513 ( 513 total )
Industry: Medical - Biomedical and Genetics
Reports 2Q11 numbers; waiting for selumetinib (MEK inhibitor) data this year
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
KSP inhibitor looks good in heavily pretreated Multiple Myeloma patients
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Industry: Medical - Biomedical and Genetics
Reports 1Q11; keeping spending in check, while advancing internal pipeline
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Industry: Medical - Biomedical and Genetics
R&Rs Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Industry: Medical - Biomedical and Genetics
13 clinical compounds at a $157M market cap: should interest investors with long-term horizon
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Industry: Medical - Biomedical and Genetics
presents Phase I data from KSP inhibitor trial in Multiple Myeloma.
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S